Press release
Bronchopulmonary Dysplasia Clinical Trial Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Research. Learn more about our innovative pipeline today! @ https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Bronchopulmonary Dysplasia Pipeline Report
* On February 06, 2026, Airway Therapeutics Inc. announced a Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing Bronchopulmonary Dysplasia (BPD) in High-Risk Preterm Neonates Compared to Standard of Care (SOC).
* In January 2026, OHB Neonatology Ltd . initiated a study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
* DelveInsight's Bronchopulmonary Dysplasia pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Bronchopulmonary Dysplasia treatment.
* The leading Bronchopulmonary Dysplasia Companies such as Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc . and others.
* Promising Bronchopulmonary Dysplasia Pipeline Therapies such as Zelpultide alfa, Inhaled Nitric Oxide, Sildenafil, Pneumostem Registered , Curosurf, OHB-607, Infasurf, Palivizumab and others.
Download for updates and be a part of the revolution in Respiratory Diseases Care @ Bronchopulmonary Dysplasia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bronchopulmonary Dysplasia Emerging Drugs Profile
* AT-100: Airway Therapeutics, Inc
Zelpultide alfa, also known as AT-100, is a novel biologic developed by Airway Therapeutics, Inc. It is a recombinant version of the human surfactant protein D (rhSP-D), engineered to reduce inflammation and infection while modulating the immune response. This therapeutic candidate primarily targets bronchopulmonary dysplasia (BPD). Currently, the drug is in the Phase III stage of its development for the treatment of Bronchopulmonary dysplasia.
* OHB-607: Oak Hill Bio
OHB-607, previously known as TAK-607, is a novel therapeutic candidate developed by Oak Hill Bio, aimed at addressing significant health challenges faced by extremely premature infants. This investigational drug is a recombinant version of insulin-like growth factor 1 (IGF-1), combined with its binding protein IGFBP-3. It is specifically designed to prevent bronchopulmonary dysplasia (BPD). OHB-607 aims to restore IGF-1 levels to those typically present in full-term pregnancies, thereby supporting the normal growth and development of vital organs like the lungs, brain, and eyes. Currently, the drug is in the Phase II stage of its development for the treatment of Bronchopulmonary dysplasia.
The Bronchopulmonary Dysplasia Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Bronchopulmonary Dysplasia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchopulmonary Dysplasia Treatment.
* Bronchopulmonary Dysplasia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Bronchopulmonary Dysplasia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchopulmonary Dysplasia market.
Learn more about Bronchopulmonary Dysplasia Drugs opportunities in our groundbreaking Bronchopulmonary Dysplasia research and development projects @ Bronchopulmonary Dysplasia Unmet Needs [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bronchopulmonary Dysplasia Companies
Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc . and others.
Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Bronchopulmonary Dysplasia Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Stay informed about how we're transforming the future of Respiratory Disease @ Bronchopulmonary Dysplasia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Bronchopulmonary Dysplasia Pipeline Report
* Coverage- Global
* Bronchopulmonary Dysplasia Companies- Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc . and others.
* Bronchopulmonary Dysplasia Pipeline Therapies- Zelpultide alfa, Inhaled Nitric Oxide, Sildenafil, Pneumostem Registered , Curosurf, OHB-607, Infasurf, Palivizumab and others.
* Bronchopulmonary Dysplasia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bronchopulmonary Dysplasia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Bronchopulmonary Dysplasia Pipeline on our website, @ Bronchopulmonary Dysplasia Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Bronchopulmonary Dysplasia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Bronchopulmonary Dysplasia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* AT-100: Airway Therapeutics, Inc
* Mid Stage Products (Phase II)
* OHB-607: Oak Hill Bio
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Bronchopulmonary Dysplasia Key Companies
* Bronchopulmonary Dysplasia Key Products
* Bronchopulmonary Dysplasia- Unmet Needs
* Bronchopulmonary Dysplasia- Market Drivers and Barriers
* Bronchopulmonary Dysplasia- Future Perspectives and Conclusion
* Bronchopulmonary Dysplasia Analyst Views
* Bronchopulmonary Dysplasia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchopulmonary-dysplasia-clinical-trial-pipeline-gains-momentum-10-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bronchopulmonary Dysplasia Clinical Trial Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight here
News-ID: 4402131 • Views: …
More Releases from ABNewswire
Stocks Under $5 to Watch Now: LRMR, RXRX, NDRA, BTQ, CDIO Watch Now!
As investors search for "stocks under $5 to buy now," "small-cap growth stocks 2026," "AI healthcare stocks," "quantum computing stocks," and "emerging Nasdaq breakout stocks," several under-the-radar companies are drawing increased attention across financial media platforms and AI-driven discovery engines including Google AI, Grok, Meta AI, ChatGPT, Microsoft Copilot, and Perplexity AI.
Here's a forward-looking look at five Nasdaq-listed names positioned across high-growth sectors:
Larimar Therapeutics, Inc. (Nasdaq: LRMR)
Rare Disease Biotech Catalyst…
Stocks Under $1 XWEL, TOON, KIDZ, HCWC to Watch Now - More Co's Inside
As investors search for "stocks under $1 to buy now," "small-cap breakout stocks 2026," "AI education stocks," "wellness growth stocks," "organic grocery expansion," and "microcap acquisition targets," several emerging companies across Nasdaq, NYSE American, and OTC markets are generating renewed attention.
Below is a forward-looking look at small-cap stocks positioned around capital raises, AI integration, revenue growth, and strategic partnerships.
XWELL, Inc. (Nasdaq: XWEL) is a global wellness company delivering science-backed services…
Microcap Stocks: AMLM, NGTF, BMXI, FAGI, RNWF Gaining Momentum - More Inside
As investors increasingly search for "OTC breakout stocks," "gold stocks under $1," "critical minerals penny stocks," "renewable energy microcaps," and "blockchain infrastructure stocks," a select group of OTC-listed companies is drawing speculative interest heading into 2026.
Below is a forward-looking look at eight OTC companies operating across critical minerals, precious metals, consumer wellness, renewable fuels, apparel manufacturing, mineral exploration, and digital asset infrastructure.
American Lithium Materials, Inc. (OTC: AMLM)
American Lithium Materials is…
LifeWellMD unveils 2026 men's performance and longevity lab in Palm Beach and Po …
LifeWellMD, a physician-led integrative clinic, announces a 2026 Men's Performance and Longevity Lab in North Palm Beach and Port St. Lucie, offering comprehensive, preventive men's health and wellness programs for busy professionals.
North Palm Beach, FL - February 20, 2026 - LifeWellMD, a physician-led integrative medical clinic, today announced the launch of its 2026 Men's Performance and Longevity Lab serving men in North Palm Beach, Port St. Lucie, and surrounding communities.…
More Releases for Bronchopulmonary
Bronchopulmonary Dysplasia Market: Expanding Revenue Landscape to 2034 - DelveIn …
DelveInsight's "Bronchopulmonary Dysplasia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bronchopulmonary Dysplasia, historical and forecasted epidemiology as well as the Bronchopulmonary Dysplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Bronchopulmonary Dysplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bronchopulmonary Dysplasia Market Forecast
https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key…
Bronchopulmonary Dysplasia (BPD) Patient Pool Analysis and Market Forecast 2024- …
Introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants requiring prolonged mechanical ventilation or supplemental oxygen. It remains one of the most serious complications of preterm birth, with lasting effects on pulmonary function, growth, and neurodevelopment.
The condition not only drives neonatal intensive care unit (NICU) costs but also increases long-term healthcare utilization for affected children. Growing global rates of preterm birth, along with improvements in neonatal…
Bronchopulmonary Dysplasia (BPD) Epidemiology Market Analysis
Bronchopulmonary Dysplasia (BPD) represents one of the most significant complications of preterm birth, affecting the respiratory system of premature infants and creating substantial healthcare challenges worldwide. The BPD epidemiology market encompasses therapeutic interventions, diagnostic tools, and supportive care technologies designed to address this chronic lung disease affecting neonates. As medical advances continue to improve survival rates among extremely premature infants, the prevalence of BPD has correspondingly increased, driving demand for…
Bronchopulmonary Dysplasia Treatment Market Growth Projections and Trends (2023- …
Bronchopulmonary Dysplasia (BPD) Treatment Market
Global Bronchopulmonary Dysplasia Treatment Market Overview
The global bronchopulmonary dysplasia (BPD) treatment market is poised for significant growth in the coming years. The market was valued at USD X billion in 2023 and is expected to reach USD Y billion by 2030, expanding at a CAGR of Z% from 2024 to 2030. With advancements in neonatal care and increasing awareness about BPD treatment options, the demand for…
Bronchopulmonary Dysplasia Pipeline Therapeutics Assessment Report 2024 (Updated …
DelveInsight's, "Bronchopulmonary Dysplasia Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Research. Learn more…
Bronchopulmonary Dysplasia Treatment Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Bronchopulmonary Dysplasia Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
BDP Market Size And Scope
The global BDP (Butane Diol Propylene) market is witnessing steady growth, fueled by its diverse applications in industries such as…
